KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $1.3 million.

  • Emergent BioSolutions' Change in Accured Expenses fell 9674.19% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.1 million, marking a year-over-year decrease of 115540.54%. This contributed to the annual value of -$18.2 million for FY2024, which is 6732.5% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Change in Accured Expenses stood at $1.3 million, which was down 9674.19% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Change in Accured Expenses registered a high of $39.9 million during Q3 2024, and its lowest value of -$51.1 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$15.4 million (2021), whereas its average is -$9.3 million.
  • Per our database at Business Quant, Emergent BioSolutions' Change in Accured Expenses surged by 44380.95% in 2021 and then tumbled by 28118.81% in 2022.
  • Over the past 5 years, Emergent BioSolutions' Change in Accured Expenses (Quarter) stood at $10.1 million in 2021, then plummeted by 281.19% to -$18.3 million in 2022, then plummeted by 39.34% to -$25.5 million in 2023, then crashed by 100.39% to -$51.1 million in 2024, then surged by 102.54% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $3.9 million for Q2 2025, and -$32.2 million during Q1 2025.